Bausch + Lomb Co. (NYSE:BLCO) Position Decreased by Trexquant Investment LP

Trexquant Investment LP reduced its stake in Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 70.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,147 shares of the company's stock after selling 46,127 shares during the period. Trexquant Investment LP's holdings in Bausch + Lomb were worth $346,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BLCO. Blue Trust Inc. lifted its position in shares of Bausch + Lomb by 68.3% during the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock worth $48,000 after buying an additional 1,004 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Bausch + Lomb during the fourth quarter worth about $72,000. Commonwealth Equity Services LLC acquired a new stake in shares of Bausch + Lomb in the 4th quarter valued at about $181,000. Orion Portfolio Solutions LLC purchased a new stake in Bausch + Lomb in the fourth quarter valued at approximately $225,000. Finally, Verition Fund Management LLC acquired a new stake in shares of Bausch + Lomb in the third quarter valued at approximately $302,000. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Bausch + Lomb Trading Down 2.5 %

NYSE:BLCO traded down $0.31 during trading hours on Tuesday, reaching $11.95. 563,499 shares of the company were exchanged, compared to its average volume of 615,398. Bausch + Lomb Co. has a 52-week low of $10.46 and a 52-week high of $21.69. The firm has a market cap of $4.22 billion, a price-to-earnings ratio of -13.13, a PEG ratio of 0.85 and a beta of 0.54. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.60 and a quick ratio of 1.01. The stock has a 50 day simple moving average of $14.86 and a 200 day simple moving average of $17.51.

Remove Ads

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its earnings results on Wednesday, February 19th. The company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.02. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter last year, the firm posted $0.24 EPS. The business's revenue for the quarter was up 9.1% compared to the same quarter last year. As a group, analysts predict that Bausch + Lomb Co. will post 0.74 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on BLCO. Bank of America reduced their price objective on Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a research note on Thursday, February 20th. Stifel Nicolaus reduced their price target on Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating for the company in a report on Thursday, April 3rd. HC Wainwright reiterated a "buy" rating and issued a $23.00 price target on shares of Bausch + Lomb in a report on Tuesday, February 18th. Wells Fargo & Company reissued an "equal weight" rating and set a $15.00 price objective (down previously from $24.00) on shares of Bausch + Lomb in a report on Friday, March 28th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Bausch + Lomb in a report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $18.82.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.